NANO-X IMAGING LTD (NNOX) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 21 (OVERSOLD (<32))
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While NNOX currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.63) and Max Pain ($0.33) forces dealer call-delta covering toward $4.95.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
NANO-X IMAGING LTD (NNOX) dropped -4.82% to $0.31, trading at 2% of its 52-week range ($0.28 – $4.71). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Nanox is working to make advanced medical imaging more accessible through digital 3D tomosynthesis technology designed to enhance visualization beyond conventional X-rays. Its Nanox.ARC platform combines imaging hardware
Gainers XORTX Therapeutics (NASDAQ:XRTX) shares moved upwards by 19.3% to $1.14 during Tuesday's after-market session. The company's market cap stands at $1.8 million. Edesa Biotech (NASDAQ:EDSA) shares rose
LOS ANGELES, CA - October 19, 2026 (NEWMEDIAWIRE) - Nanox (NASDAQ: NNOX) announced that its subsidiary, Nanox AI Ltd., has entered into a distribution agreement with Technologic s.r.l., an Italian company affiliated with
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +15.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on NNOX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for NNOX. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, NANO-X IMAGING LTD (NNOX) ranks #898 by composite RQD confidence (32/100, grade E) and #822 by equity capitalization ($24.0M). Within this direct 5-issuer industry benchmark cohort, GEHC leads on earnings valuation at 16.6x trailing P/E, while GEHC leads on capital efficiency and profitability with 14.2% ROIC and 40.0% gross margin. GEHC currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with NNOX at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NNOX
ACTIVE
NANO-X IMAGING LTD | E | 32/100 | — | -30.0% | -35.0% | -4.82% | $24.0M | Benchmark Subject |
| BFLY Butterfly Network Inc. (Class A) | D- | 38/100 | — | 46.9% | -35.0% | -3.84% | $2.00B | /bfly-vs-nnox → |
| PHG Koninklijke Philips N.V. NY Registry Shares | D+ | 58/100 | 32.8x | — | 9.9% | +0.33% | $26.66B | /phg-vs-nnox → |
| GEHC GE HealthCare Technologies Inc. | C | 65/100 | 16.6x | 40.0% | 14.2% | +0.79% | $34.55B | /gehc-vs-nnox → |
| MIRA MIRA Pharmaceuticals Inc. | D | 48/100 | — | — | -35.0% | +2.79% | $24.0M | /mira-vs-nnox → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), NANO-X IMAGING LTD (NNOX) reported GAAP revenue of $13.0M (+15.4% vs. FY2024 revenue of $11.3M , and +31.5% cumulative change since FY2023) , GAAP net income of -$75.0M, operating cash flow of -$40.8M, and free cash flow of -$45.0M (-14.3% YoY). On the balance sheet, NNOX closed FY2025 with $162.2M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $13.0M | -$75.0M | -$40.8M | -$45.0M | $162.2M | — |
| FY2024 (FY) | 2024-12-31 | $11.3M | -$53.5M | -$36.6M | -$39.4M | $210.0M | — |
| FY2023 (FY) | 2023-12-31 | $9.9M | -$60.8M | -$44.8M | -$44.8M | — | — |
As of 2026-11-01, NANO-X IMAGING LTD (NASDAQ: NNOX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $0.31 (-4.82% 1D, market cap $24.0M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NNOX ranks #898 in composite RQD confidence.
Within the Health Care sector (Medical Electronics), NNOX carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, BFLY (Butterfly Network Inc. (Class A)) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $2.00B) and PHG (Koninklijke Philips N.V. NY Registry Shares) posts a D+ grade (58/100 RQD, P/E 32.8x, ROIC 9.9%, cap $26.66B). Among the 5-stock peer group, GEHC leads on earnings multiple (16.6x) while GEHC leads on capital efficiency (14.2% ROIC).
Per NNOX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001795251), NANO-X IMAGING LTD generated $13.0M in revenue (+15.4% YoY), -$75.0M in net income, and -$45.0M in free cash flow against $162.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
NNOX last traded at $0.31 (-4.82% on volume of 1,250,165 shares), positioning the stock -50.79% below its 50-day simple moving average ($0.63) and -80.63% below its 200-day simple moving average ($1.60). Across its 52-week range of $0.28 to $4.71, NNOX sits at the 0.7% percentile with a 14-day RSI of 21.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.35).
Why NNOX Stock dropped -4.82% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.